TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25569654
Drug: Fentanyl combined
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl combined with etomidate (fentanyl 1 to 2 μg/kg, etomidate 0.1 to 0.3 mg/kg)
Study: 29751193
Drug: Low added
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low added sugar adequate fiber diet (LASAF; 5% total energy from AS and 13.5 g fiber/1000 kcal)
Study: 17029618
Drug: RF-NaP 32
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RF-NaP 32 tablets (48 g)
Study: 9425505
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist and calcium, with or without nasal salmon calcitonin
Study: 4604478
Drug: Ogawa vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ogawa vaccine
Study: 30635477
Drug: Rituximab induction
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab induction followed by glatiramer acetate (GA) monotherapy
Study: 9301631
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin twice a day
Study: 23127169
Drug: Photosensitizer group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photosensitizer group (tolouidine blue O, 0.1 mg/ml)
Study: 20526200
Drug: Dynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic treatment regimen (take hormone therapy until certain adverse events become apparent, then stop)
Study: 17318527
Drug: Enteral nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral nimodipine (60 mg tablet/suspension at 4-h intervals)
Study: 17318527
Drug: Intravenous nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nimodipine (2 mg/h continuous infusion)
Study: 15241347
Drug: Pranlukast 300
Normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pranlukast 300 mg twice daily
Study: 23754545
Drug: mesalazine 800
Normalized name: mesalazine 800 MG Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalazine 800 mg twice daily for 10 days every month
Study: 12466334
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of long-term GH treatment
Study: 10769103
Drug: Nerve root
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve root injection of 0.10 g of lidocaine hydrochloride and 3.75 mg of cortivazol
Study: 10421236
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of [1‐13C]alanine for 3.5 hours
Study: 10421236
Drug: Nasogastric tube
Normalized name: nasogastric tube
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasogastric tube infusion of [1‐13C]alanine for 3.5 hours
Study: 8751234
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily for 7 days
Study: 14503053
Drug: WM group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: WM group (chemotherapy)
Study: 21677054
Drug: Protein-energy supplements
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-energy supplements (1015 kcal and 22 g protein/d) provided to pregnant women from 20 weeks gestation until delivery
Study: 9383487
Drug: Fast injection
Normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast injection of unbuffered lidocaine
Study: 30273622
Drug: Topical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin analog (latanoprost)
Study: 12969089
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg o.d., tinidazole 500 mg b.d., rabeprazole 20 mg b.d. for 10 days (LTR)
Study: 2903936
Drug: Benzodiazepine antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Benzodiazepine antagonist
Study: 25886536
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution and standard care
Study: 15480128
Drug: Fluoroscopically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopically guided bilateral facet injections plus supervised stretching exercises (Group A, n = 36)
Study: 20498389
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg/d
Study: 3141640
Drug: Lipid infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion
Study: 9033441
Drug: Inhaled broxaterol
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled broxaterol 400 micrograms t.i.d.
Study: 9931626
Drug: Neoadjuvant radio-
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant radio- and/or chemotherapy
Study: 9280178
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil plus sunflower oil (average EPA + DHA intake: 5.2 g/d)
Study: 8393884
Drug: Aspirin (oral)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (oral)
Study: 27154871
Drug: Simulated pills
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated pills (Control)
Study: 10845730
Drug: Levetiracetam 2000
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 2000 mg daily
Study: 23299064
Drug: Cefuroxime 250
Normalized name: cefuroxime 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 250 mg twice daily for 10 days (n=57)
Study: 27348693
Drug: Structured exercise
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured exercise group (non-operative treatment)
Study: 541683
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis B vaccine
Study: 21482964
Drug: High-dose multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose multivitamin (folic acid, vitamin B6, and vitamin B12)
Study: 12171372
Drug: Family intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Family intervention (single family therapy)
Study: 30201821
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment
Study: 15121121
Drug: Dermagraft and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermagraft and compression therapy
Study: 31575585
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections (BOTOX) at 8 UI/kg in the internal shoulder rotator muscles
Study: 18566882
Drug: LEGO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEGO therapy
Study: 8636309
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg finasteride daily for 3 months to 4 years (group 3)
Study: 8636309
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg finasteride daily for 23-73 days (group 2)
Study: 16649870
Drug: Hypnotic analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic analgesia suggestion
Study: 22409388
Drug: Vicodin (hydrocodone/acetaminophen)
Normalized name: acetaminophen / hydrocodone bitartrate Oral Tablet [Vicodin]
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vicodin (hydrocodone/acetaminophen)
Study: 28271251
Drug: Gliclazide added
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide added to metformin/sitagliptin
Study: 9405910
Drug: GLP-1 tablet
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 tablet
Study: 31526218
Drug: Heat-stable rotavirus
Normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stable rotavirus vaccine (HSRV)
Study: 25056361
Drug: Shanchol vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shanchol vaccine
Study: 1599636
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg felodipine
Study: 23817921
Drug: Myelin peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myelin peptide skin patch (1 mg)
Study: 8683863
Drug: Interleukin-3 (IL-3)
Normalized name: interleukin-3
DrugBank: Muplestim (DB12431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-3 (IL-3) therapy, daily subcutaneous doses of 2.5, 5.0 or 7.5 micrograms/kg for 7 or 14 days
Study: 4013351
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg spironolactone + 5 mg butizide (SB)
Study: 4013351
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg spironolactone + 20 mg furosemide (SF)
Study: 29546527
Drug: 10 hours
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 hours bed rest after intrathecal chemotherapy
Study: 3289830
Drug: isoxicam 200
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isoxicam 200 mg
Study: 12533165
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution (control)
Study: 31952923
Drug: rVSVN4CT1-EBOVGP1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSVN4CT1-EBOVGP1 vaccine (2·5×10^4 PFU, 2×10^5 PFU, 1·8×10^6 PFU)
Study: 31952923
Drug: rVSVN4CT1-EBOVGP1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSVN4CT1-EBOVGP1 vaccine
Study: 9641566
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SIT)
Study: 11240959
Drug: Atopy patch
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopy patch test (APT)
Study: 24427279
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day DHA from 16 wk gestation to delivery
Study: 19006471
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg rosuvastatin alone
Study: 12414411
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 0.3% applied 1 hour before surgery
Study: 9737101
Drug: TTS fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TTS fentanyl (25, 50, 75, or 100 micrograms/hr) administered as a transdermal patch every 3 days
Study: 8287749
Drug: Oral mesalazine
Normalized name: mesalamine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mesalazine (0.5 g three times/day)
Study: 1464341
Drug: Captopril low
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril low dose group (incremental doses of 6.25, 12.5, and 25.0 mg)
Study: 4054194
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg once daily
Study: 3897071
Drug: Prazosin 2
Normalized name: prazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 2 mg twice a day
Study: 8796773
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous bolus of ephedrine (10 mg)
Study: 23715924
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (300 mg magnesium as citrate)
Study: 27444761
Drug: Betamethasone gel
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone gel
Study: 9706829
Drug: ACE-inhibitors started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ACE-inhibitors started within the first day after acute myocardial infarction and continued for 4 to 6 weeks.
Study: 9706829
Drug: ACE-inhibitors for
Normalized name: Gastric inhibitory polypeptide
DrugBank: Gastric inhibitory polypeptide (DB15217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitors for patients with LVD.
Study: 9706829
Drug: ACE-inhibitors for
Normalized name: Gastric inhibitory polypeptide
DrugBank: Gastric inhibitory polypeptide (DB15217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitors for patients without evidence of LVD.
Study: 2654350
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (free alpha-tocopherol) administered parenterally and later orally at pharmacologic serum levels (5 mg/dl)
Study: 2654350
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (free alpha-tocopherol) administered for greater than or equal to 8 days
Study: 889333
Drug: Salicylic acid
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic acid 2% cream
Study: 30572894
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g placebo
Study: 17227802
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate 70 mg/wk
Study: 3819391
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg t.i.d. for 3 days
Study: 10695793
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg once a day for 3 days
Study: 19846008
Drug: Low-tidal-volume group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-tidal-volume group (tidal volume no more than 6 ml/kg of predicted body weight)
Study: 17241418
Drug: Topical botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical botulinum toxin type A (BTX‐A) 200 U applied to one axilla
Study: 10853619
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 10 mg/kg (as caffeine base) administered intravenously, followed by 2.5 mg/kg/day orally or intravenously, for up to 10 days.
Study: 23018283
Drug: Clozapine suspension
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine suspension (50 mg/mL)
Study: 22117974
Drug: Molecular target
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular target therapy gefitinib (group I)
Study: 6741668
Drug: High maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: High maintenance doses of methadone (Group 1) for a 14-week period
Study: 12213433
Drug: Carnitine treatment
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carnitine treatment
Study: 11561033
Drug: Respiratory therapy
Normalized name: respiratory therapy supplies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory therapy (RET)
Study: 3542496
Drug: Colchicine therapy
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine therapy (4 X 0.25 mg/d for five days a week)
Study: 22234594
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality (VR) training simulator for hysteroscopic placement of tubal sterilization implants
Study: 796755
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg chlorpromazine‐‐250 mg alpha‐methyldopa/day
Study: 3315283
Drug: Intramuscular methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular methotrexate
Study: 963493
Drug: Antitrichomonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antitrichomonal therapy
Study: 29226816
Drug: Intravenous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous furosemide (IV), mean dose: 123 ± 47 mg
Study: 29226816
Drug: Intravenous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous furosemide (IV)
Study: 22958024
Drug: Extra-protein group
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-protein group (4.8 g kg(‐1) per day)
Study: 17436778
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (Cr) 20 g/day for 7 days
Study: 19237980
Drug: CSL 10
Normalized name: CSL-689
DrugBank: CSL-689 (DB17726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL 10 ml/kg
Study: 7867678
Drug: mizolastine 40
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mizolastine 40 mg
Study: 14707789
Drug: Intensification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification of standard antiretroviral therapy with abacavir, with or without efavirenz.
Study: 30771686
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4.4 g/d)
Study: 8929936
Drug: Social model
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social model residential program providing integrated mental health and substance abuse treatment
Study: 26286532
Drug: Post-treatment predictor
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment predictor models
Study: 21127322
Drug: Intracoronary autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary autologous bone marrow cell infusion (BMC)
Study: 26763495
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy
Study: 19454032
Drug: Haloperidol 0.5
Normalized name: haloperidol 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 0.5 to 2 mg/hour (with or without loading doses of 2.5 mg)
Study: 31167027
Drug: Antimicrobial stewardship
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial stewardship programme (ASP) with an appointed antibiotic advisor (AA)
Study: 30987663
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) supplementation (0.2 g/kg body mass)
Study: 10594487
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg itraconazole
Study: 3721047
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (i.v. infusion of Hydralazine and MgSO4)
Study: 10582134
Drug: HD-EPI 120
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-EPI 120 mg/m2 + CP 60 mg/m2
Study: 15295955
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg with hydrocodone 5 mg
Study: 18094224
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg alone
Study: 12132977
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (150 mg, twice daily for 7 weeks)
Study: 28416344
Drug: Sunbed intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunbed intervention (twice weekly exposure for 12 weeks)
Study: 25087839
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg BIW for < 12 weeks (or ETN 25 mg BIW for an extra 12 weeks until PGA < 2 was achieved) during Cycle 1
Study: 9040549
Drug: Formula 8
Normalized name: Joint Formula 88 Max Plus
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula 8 (iron approximately 143 mumol/L or 8 mg/L)
Study: 29560939
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg orally per day
Study: 24809838
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine infusion
Study: 21914315
Drug: Propafenone 150
Normalized name: propafenone 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 150 mg, 3 times a day